UBS Group’s TScan Therapeutics TCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $581K | Buy |
400,401
+276,960
| +224% | +$402K | ﹤0.01% | 4730 |
|
|
2025
Q1 | $170K | Buy |
123,441
+31,581
| +34% | +$43.6K | ﹤0.01% | 5403 |
|
|
2024
Q4 | $279K | Buy |
91,860
+72,516
| +375% | +$220K | ﹤0.01% | 5055 |
|
|
2024
Q3 | $96.3K | Buy |
19,344
+6,699
| +53% | +$33.4K | ﹤0.01% | 5210 |
|
|
2024
Q2 | $74K | Buy |
12,645
+10,744
| +565% | +$62.9K | ﹤0.01% | 5244 |
|
|
2024
Q1 | $15.1K | Buy |
1,901
+477
| +33% | +$3.79K | ﹤0.01% | 5875 |
|
|
2023
Q4 | $8.3K | Buy |
1,424
+309
| +28% | +$1.8K | ﹤0.01% | 6359 |
|
|
2023
Q3 | $2.85K | Buy |
1,115
+15
| +1% | +$38 | ﹤0.01% | 6493 |
|
|
2023
Q2 | $2.75K | Sell |
1,100
-2,140
| -66% | -$5.35K | ﹤0.01% | 6621 |
|
|
2023
Q1 | $6.8K | Buy |
3,240
+2,240
| +224% | +$4.7K | ﹤0.01% | 6783 |
|
|
2022
Q4 | $1.55K | Sell |
1,000
-2,441
| -71% | -$3.78K | ﹤0.01% | 8643 |
|
|
2022
Q3 | $11K | Buy |
3,441
+2,293
| +200% | +$7.33K | ﹤0.01% | 7227 |
|
|
2022
Q2 | $4K | Buy |
+1,148
| New | +$4K | ﹤0.01% | 8086 |
|
|
2022
Q1 | – | Sell |
-811
| Closed | -$4K | – | 9601 |
|
|
2021
Q4 | $4K | Sell |
811
-135
| -14% | -$666 | ﹤0.01% | 8424 |
|
|
2021
Q3 | $8K | Buy |
+946
| New | +$8K | ﹤0.01% | 7077 |
|